Caribou Biosciences Company Insiders
| CRBU Stock | USD 1.04 0.04 4.00% |
Caribou Biosciences employs about 147 people. The company is managed by 14 executives with a total tenure of roughly 343 years, averaging almost 24.0 years of service per executive, having 10.5 employees per reported executive. Breaking down Caribou Biosciences' management performance can provide insight into the firm performance.
Caribou |
Caribou Biosciences Management Team Effectiveness
The company has return on total asset (ROA) of (0.2718) % which means that it has lost $0.2718 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4799) %, meaning that it created substantial loss on money invested by shareholders. Caribou Biosciences' management efficiency ratios could be used to measure how well Caribou Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.Caribou Biosciences Workforce Comparison
Caribou Biosciences is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 3,154. Caribou Biosciences holds roughly 147 in number of employees claiming about 5% of equities under Health Care industry.
Caribou Biosciences Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Caribou Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Caribou Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Caribou Biosciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Ryan Fischesser over two weeks ago Insider Trading | ||
Albertson Tina M. over two weeks ago Acquisition by Albertson Tina M. of 66137 shares of Caribou Biosciences at 1.41 subject to Rule 16b-3 | ||
Khan Ruhi Ahmad over two months ago Acquisition by Khan Ruhi Ahmad of 70000 shares of Caribou Biosciences subject to Rule 16b-3 | ||
Whiting Nancy over two months ago Acquisition by Whiting Nancy of 21500 shares of Caribou Biosciences at 6.12 subject to Rule 16b-3 | ||
Rizvi Syed Ali-aamir over three months ago Acquisition by Rizvi Syed Ali-aamir of 131000 shares of Caribou Biosciences at 6.12 subject to Rule 16b-3 | ||
Ryan Fischesser over three months ago Insider Trading | ||
Rachel Haurwitz over three months ago Acquisition by Rachel Haurwitz of 10000 shares of Caribou Biosciences at 2.96 subject to Rule 16b-3 | ||
Khan Ruhi Ahmad over three months ago Acquisition by Khan Ruhi Ahmad of 131000 shares of Caribou Biosciences at 6.12 subject to Rule 16b-3 |
Caribou Biosciences Notable Stakeholders
A Caribou Biosciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Caribou Biosciences often face trade-offs trying to please all of them. Caribou Biosciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Caribou Biosciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Sriram MBA | Chief Officer | Profile | |
| Amy CFA | Vice Communications | Profile | |
| Cindy Hayashi | VP HR | Profile | |
| Ryan Fischesser | Interim Controller | Profile | |
| Jason MBA | Chief Officer | Profile | |
| JD Esq | Chief Secretary | Profile | |
| Timothy MBA | Chief Officer | Profile | |
| Reigin Zawadzki | Chief Officer | Profile | |
| Syed MD | Chief Officer | Profile | |
| Rachel Haurwitz | CEO, CoFounder | Profile | |
| Steven Kanner | Chief Officer | Profile | |
| Ruhi MBA | Chief Officer | Profile | |
| Justin Skoble | VP Operations | Profile | |
| Daniel Poon | Vice Technology | Profile |
About Caribou Biosciences Management Performance
The success or failure of an entity such as Caribou Biosciences often depends on how effective the management is. Caribou Biosciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Caribou management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Caribou management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. The company was incorporated in 2011 and is headquartered in Berkeley, California. Caribou Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange.
Please note, the imprecision that can be found in Caribou Biosciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Caribou Biosciences. Check Caribou Biosciences' Beneish M Score to see the likelihood of Caribou Biosciences' management manipulating its earnings.
Caribou Biosciences Workforce Analysis
Traditionally, organizations such as Caribou Biosciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Caribou Biosciences within its industry.Caribou Biosciences Manpower Efficiency
Return on Caribou Biosciences Manpower
| Revenue Per Employee | 68K | |
| Revenue Per Executive | 713.9K | |
| Net Loss Per Employee | 1M | |
| Net Loss Per Executive | 10.7M | |
| Working Capital Per Employee | 1.3M | |
| Working Capital Per Executive | 13.5M |
Additional Tools for Caribou Stock Analysis
When running Caribou Biosciences' price analysis, check to measure Caribou Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Caribou Biosciences is operating at the current time. Most of Caribou Biosciences' value examination focuses on studying past and present price action to predict the probability of Caribou Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Caribou Biosciences' price. Additionally, you may evaluate how the addition of Caribou Biosciences to your portfolios can decrease your overall portfolio volatility.